NewsNation covers research aimed at the weight many people put back on once they come off GLP-1 medications.
Recap by typeshit. Full story at NewsNation.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A projection framing weight loss drugs as a growing slice of American healthcare spending. Thin on detail beyond the market forecast.
The poster argues Mounjaro and Zepbound are getting easier to obtain and that coaches should watch for them on their teams. Only a short excerpt is available.
Loading…